A retrospective study found increased axillary lymph node uptake on PET scans after COVID-19 vaccination, affecting 7.4% of FDG and 23.1% of 11C-choline PET examinations. Ipsilateral deltoid uptake was also observed in 14.5% of examinations.
Researchers are studying the effectiveness and safety of COVID-19 vaccines during pregnancy, using data from Ontario's vaccination registry and province-wide birth registry. The study aims to inform decision-making for ongoing COVID-19 vaccine administration programs in Canada.
A recent study published in PLOS ONE found that individuals relying on traditional news sources are more accepting of the COVID-19 vaccine. The research highlights the importance of trusted sources in shaping public opinion on vaccination.
Researchers developed a microparticle-based cancer vaccine that kickstarts an immune response, increasing the proportion of mice cured of tumors to 75%. Combining the vaccine with immune checkpoint inhibitors greatly improves treatment success, offering a promising approach to improving cancer treatment.
Researchers have successfully treated a patient with vaccine-induced thrombotic thrombocytopenia (VITT) using intravenous immunoglobulin concentrates, cortisone, and specific anticoagulants. Prompt diagnosis and treatment can prevent life-threatening thrombosis.
Developed by Inserm teams and French company NEOVACS, the conjugate vaccine induces sustained production of antibodies against IL-4 and IL-13, significantly reducing asthma symptoms.
Researchers have discovered a misinterpreted model of immature flavivirus particles, revealing an unexpected organisation that could lead to new and better vaccines. The study's findings define the exact wiring of the immature virus before it becomes infectious, providing a solid foundation for designing tomorrow's treatments.
Researchers recommend surveillance, accurate diagnosis, and rapid response to counteract COVID-19 misinformation and disinformation. They also introduce a taxonomy of categories for different types of misinformation related to Covid-19 and vaccination.
A new COVID-19 vaccine developed using the Sementis Copenhagen Vector (SCV) platform is being accelerated for human clinical trials within 18 months. The vaccine aims to provide long-term and broad-ranging immunity against SARS-CoV-2, including mutant strains.
A new study from Beth Israel Deaconess Medical Center found that COVID-19 mRNA vaccines triggered immune responses in pregnant and lactating women, with maternal antibodies transferred to infant cord blood and breast milk. This suggests that vaccinating pregnant mothers may protect infants from COVID-19 infection.
A new study examines the safety of COVID-19 vaccines in patients with cancer, providing insights into potential risks and benefits. The research found that while some cancer treatments may interact with COVID-19 vaccines, the overall risk is low.
A UCR study found that messages stressing the Christian doctrine of 'love thy neighbor' and aligning mask-wearing with patriotism can effectively persuade white evangelicals to wear masks. The research also suggests that similar messaging could be used for pro-vaccine efforts, particularly targeting Republican-leaning individuals.
Research from the Com-COV study shows that mixing COVID-19 vaccine doses can lead to more frequent mild-moderate symptoms, but adverse reactions are short-lived and no safety concerns were found. The study's findings suggest that mixed schedules could result in increased work absences after vaccination.
A dengue virus vaccine candidate has produced a protective immune response in infected mice, offering a promising alternative to existing vaccines. The UQ-developed vaccine uses an Australian insect virus and can be administered via a microarray patch for easy, needle-free delivery.
A new study by Stanford researchers found that nearly two-thirds of California prison residents who were offered a COVID-19 vaccine accepted at least one dose. Acceptance rates varied across different racial and ethnic groups, with Hispanic and white inmates having the highest acceptance rates.
A US study suggests that delaying the second dose of COVID-19 vaccines for people under 65 could result in lower mortality rates, with estimates suggesting a 20% reduction in deaths. The strategy is optimal when vaccine efficacy from one dose is 80% or higher and vaccination rates are low.
A study published in JAMA Dermatology reports delayed localized injection-site reactions to the Moderna COVID-19 vaccine in 16 patients. The authors highlight this finding as a potential side effect of the vaccine, emphasizing the importance of monitoring for such reactions.
Researchers at Scripps Research have unveiled an innovative Ebola virus vaccine design that stimulates a better protective immune response. The new approach involves tethering copies of the Ebola virus outer spike protein to a spherical carrier particle, resulting in a more stable and realistic-looking virus particle.
A new UNSW Sydney study examines content between December 2019 to November 2020 and found over 103 million people globally shared or reacted with misinformation about COVID-19 vaccines. The study highlights the need for traditional risk communication and community engagement methods to counter misinformation.
Frontline healthcare workers may face temporary redeployment if they refuse COVID-19 vaccination, according to ethicists. A mild form of mandatory vaccination policy is justified to protect patients and colleagues.
A new Northwestern Medicine study of placentas from vaccinated patients found no evidence of injury, supporting the safety of COVID-19 vaccines in pregnancy. The study adds to growing evidence that vaccination can protect fetuses without increasing harm.
A 2011 CIA-led vaccination campaign in Pakistan led to a significant decline in vaccination rates due to distrust and misinformation. The campaign's misleading tactics created doubt about the integrity of health workers and vaccines, resulting in lower vaccination rates among girls, particularly in districts with high levels of elector...
The Hong Kong Society of Rheumatology has developed consensus recommendations for COVID-19 vaccination in adult patients with autoimmune rheumatic diseases. The guidelines address concerns about vaccine efficacy and safety, as well as considerations for immunosuppressed patients.
A new Strep A human challenge model has been successfully developed, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores. The model, which deliberately infected healthy adult volunteers with the bacteria in a controlled environment, was found to be safe and effective.
People with dementia have twice the risk for developing COVID-19, with high hospitalization rates and mortality. Alzheimer Europe urges governments to prioritize these groups in vaccination campaigns to prevent further harm.
Healthcare workers who received the Pfizer-BioNTech BNT162b2 vaccine had lower incidence of symptomatic and asymptomatic SARS-CoV-2 infections. The study found a significant association between vaccination with the BNT162b2 vaccine and reduced risk of SARS-CoV-2 infections among healthcare workers.
A new study published in the Journal of Infectious Diseases found that vaccinating half the US population by summer can prevent 5.8 million cases and $7.8 billion in societal costs. Increasing vaccination coverage to 70% can save even more lives and reduce medical costs.
A study published in JAMA found that two doses of a COVID-19 vaccine provide some protection for people with solid organ transplants, but not enough to dispense with masks and physical distancing. Immunocompromised patients should continue to practice strict COVID-19 safety measures after vaccination.
A new study by St. Jude Children's Research Hospital found that COVID-19 vaccination significantly reduced asymptomatic SARS-CoV-2 infections in employees, with a 79% risk reduction compared to unvaccinated peers.
A new report by the University of Birmingham reveals that only 41.4% of respondents in a UK-wide survey expressed interest in participating in COVID-19 vaccine trials. The study found that male graduates, those aged 40-49 and 50-59, and individuals with no health issues were more likely to be interested, while Black Asian Minority Ethn...
The study found a significant association between the Pfizer-BioNTech BNT162b2 vaccine and decreased risk of symptomatic and asymptomatic SARS-CoV-2 infections in hospital employees. Hospital employees who received the vaccine had lower rates of infection compared to those who did not receive the vaccine.
A study suggests that vaccinating older age groups first can significantly reduce disease transmission, mortality, and long-term health impacts. The research found that prioritizing the elderly and medically vulnerable ahead of younger people yields the greatest impact in minimizing loss of life.
A new study found that many lupus patients with Medicaid were unvaccinated and required more acute care for vaccine-preventable illnesses. Black patients had a higher risk of needing such care compared to white patients.
A large study found a slightly increased rate of vein blood clots, including cerebral venous thrombosis, after the first dose of the Oxford-AstraZeneca covid-19 vaccine. However, researchers stress that the risk is considered low and the benefits of vaccination still outweigh the risks for most age groups.
A new digital health solution aims to promote COVID-19 vaccination among patients with compromised health conditions like multiple sclerosis. Motivational Interviewing Conversational Agent MintBot will address vaccine hesitancy and facilitate immediate action.
Researchers found a slightly increased rate of rare blood clots, including cerebral blood clots and venous blood clots, following AstraZeneca vaccination. The absolute risk remains low, but the vaccine has been removed from Danish and Norwegian vaccination programmes due to concerns.
Two doses of the Pfizer-BioNTech vaccine provide more than 95% protection against COVID-19 infection, hospitalisation, severe illness, and death, including among the elderly. The analysis also reveals a decline in COVID-19 cases following Israel's national vaccination programme.
A new case report details the treatment of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) using bivalirudin, an alternative to heparin. Early outcomes suggest that this approach may be safe and effective in treating these rare but serious clot reactions.
A study found that users of conservative and social media were more likely to believe in COVID-19 conspiracies, with a significant increase in belief from March to July 2020. Mainstream news consumption was associated with decreased conspiracy beliefs.
The European Federation of Academies of Sciences and Humanities (ALLEA) releases a report calling for enhanced European exchange and coordination to tackle science disinformation. Key strategies include inoculation, debunking, fact-checking, and media literacy, as well as innovations in science communication.
A study by Imperial College London found that prior COVID-19 infection significantly enhances protection against the Kent and South Africa variants after a single dose of mRNA vaccine. In contrast, those without previous SARS-CoV-2 infection may not receive sufficient immune response, highlighting the importance of second doses.
A new paradigm for usability aims to address accessibility issues worldwide, with a focus on marginalized groups. The approach emphasizes the importance of user-centered design and its potential to drive improvements in various fields.
A high rate of vaccination is vital to reducing COVID-19 cases and controlling the pandemic, according to new research from the Mayo Clinic. If Minnesota had achieved a 75% vaccination rate by early April, case numbers and hospitalizations would plummet by July.
A recent study from the University of Virginia Health System found that more than a quarter of American infants in 2018 had not received all recommended childhood vaccines. Disparities were observed among African-American infants, low-income families, and those with lower education levels. The researchers warn that these gaps can lead ...
Experts warn that cerebral venous sinus thrombosis (CVST) blood clots are rare but serious events associated with COVID-19 infections, not vaccines. Immediate screening and non-heparin anticoagulants can help diagnose and treat the condition. Most patients can recover fully with proper treatment.
A Cornell-led research survey found that many Americans believe the Moderna and Pfizer-BioNTech vaccines provide weak protection against COVID-19 after a second dose. The study highlights the need for improved guidance on continued public health precautions, such as wearing masks, to combat vaccine attrition and prolong pandemic recovery.
A quality improvement study evaluated the length, readability, and complexity of COVID-19 vaccine phase III randomized clinical trial informed consent documents. The study found that these documents were often lengthy and complex, posing a barrier to participant understanding.
The article discusses the critical role of Texas Biomed in the development of the Pfizer COVID-19 vaccine through preclinical testing. Scientists tested two mRNA vaccine candidates in rhesus macaques, showing high effectiveness in protecting against SARS-CoV-2, and highlighting the importance of rapid therapy and vaccine development.
The study estimates that only about 24% of young adults aged 18 to 21 in the United States have been fully vaccinated against human papillomavirus (HPV). The low vaccination rate is a cause for concern given the significant health risks associated with HPV infection, including cervical cancer and other types of cancer.
Researchers analyzed COVID-19 vaccination data and found no significant association between mRNA vaccines and facial paralysis. The study suggests that compared to other viral vaccines, mRNA COVID-19 vaccines do not display a signal of facial paralysis.
The study found that 25.4% of vaccinated people experienced systemic side effects, with headache being the most common, while local side effects were reported by 66.2%.
A small study from Mayo Clinic researchers raises concerns that some transplant patients may have a limited immune response after receiving an mRNA COVID-19 vaccine. The study found that infected vaccinated solid organ transplant recipients had a 10 times higher infection rate compared to the general population.
Researchers are enrolling 500 participants, 400 with primary/secondary immune system disorders and 100 without, to study COVID-19 vaccine responses. The study aims to characterize features and adequacy of immune responses and provide valuable information about benefits and potential risks in individuals with immune deficiencies.
Recent polls of people aged 14 to 24 reveal most young people are taking COVID-19 seriously and motivated by a desire to protect others. They prioritize following public health guidance when near close contacts or in 'pod' situations.
A simulation modeling study estimates the benefits of identifying silent COVID-19 infections among children as a proxy for their vaccination. The study suggests that vaccination can significantly reduce future infection rates in this population.
A new study by Johns Hopkins Medicine researchers found that mRNA vaccines for COVID-19 may provide protection against the latest variant strains and even the common cold. The vaccine-induced T cell response was found to be effective in recognizing the spike proteins of both SARS-CoV-2 and three common cold coronaviruses.
Researchers at Northwestern University have discovered a new biomanufacturing platform that can increase protein-based vaccine yields by five-fold and reduce production costs to $1 per dose. The technology utilizes enriched cell-free extracts with cellular membranes, significantly broadening access to potentially lifesaving medicines.
The study found that the vaccine is highly effective across all age ranges, with 92% effectiveness in preventing symptomatic disease in individuals 70 years and older. Vaccine effectiveness varied among subpopulations, with slightly lower rates in multi-morbid populations and immunosuppressed individuals.
A synthetic DNA vaccine for MERS-CoV induced robust antibody neutralizing antibodies and cellular immune responses, protecting against MERS-CoV in NHP models. The low-dose regimen with intradermal delivery was more impactful in controlling disease than the higher dose delivered intramuscularly.
A study from Rockefeller University suggests that breakthrough COVID cases may be driven by rapid evolution of the virus. Ongoing testing of immunized individuals is crucial to mitigate future outbreaks.